Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis

References

• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019;5(8):1205–1214.
   PubMed Web of Science ®Google Scholar
• Vranic S, Cyprian FS, Gatalica Z, et al. PD-L1 status in breast cancer: current view and perspectives. Semin Cancer Biol. 2021;72:146–154.
   PubMed Web of Science ®Google Scholar
• Chang C-H, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–1241.
   PubMed Web of Science ®Google Scholar
• Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657–671.
   PubMed Web of Science ®Google Scholar
• Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–1778.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187–201 e10.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.
   PubMed Web of Science ®Google Scholar
• Sun L, Li CW, Chung EM, et al. Targeting glycosylated PD-1 induces potent antitumor immunity. Cancer Res. 2020;80(11):2298–2310.
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol . 2017;14(1):11–31.
   PubMed Web of Science ®Google Scholar
• Gong Y, Ji P, Yang Y-S, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33(1):51–64.e9.
   PubMed Web of Science ®Google Scholar
• Kim SK, Ahn SG, Mun JY, et al. Genomic signature of the standardized uptake value in (18)F-fluorodeoxyglucose positron emission tomography in breast cancer. Cancers. 2020;12(2):497.
   PubMed Web of Science ®Google Scholar
• Kang S, Kim EH, Hwang JE, et al. Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. Biochem Biophys Res Commun. 2019;511(1):185–191.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf . 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Li T, Wernersson R, Hansen RB, et al. A scored human protein-protein interaction network to catalyze genomic interpretation. Nat Methods. 2017;14(1):61–64.
   PubMed Web of Science ®Google Scholar
• Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108-e10.
   Web of Science ®Google Scholar
• Gu Y, Li X, Bi Y, et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging. 2020;12(1):784–807.
   PubMedGoogle Scholar
• Bowling EA, Wang JH, Gong F, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021;184(2):384–403.e21.
   PubMed Web of Science ®Google Scholar
• Saik OV, Klimontov VV. Bioinformatic reconstruction and analysis of gene networks related to glucose variability in diabetes and its complications. Int J Mol Sci. 2020;21(22):8691.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang JW, Xu Y, et al. Effect of β-(3,4-dihydroxyphenyl)lactic acid on oxidative stress stimulated by high glucose levels in human peritoneal mesothelial cells. J Int Med Res. 2012;40(3):943–953.
   PubMed Web of Science ®Google Scholar
• Alvarez ML, DiStefano JK. Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS One. 2011;6(4):e18671.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658.
   PubMed Web of Science ®Google Scholar
• Ahn SG, Park JT, Lee HM, et al. Standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. Breast Cancer Res. 2014;16(6):502.
   PubMed Web of Science ®Google Scholar
• Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50(11):1820–1827.
   PubMed Web of Science ®Google Scholar
• Palaskas N, Larson SM, Schultz N, et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011;71(15):5164–5174.
   PubMed Web of Science ®Google Scholar
• Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480–508.
   PubMed Web of Science ®Google Scholar
• Shimoda W, Hayashi M, Murakami K, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14(3):260–268.
   PubMedGoogle Scholar
• Ahn SG, Lee J-H, Lee HW, et al. Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. PLoS One. 2017;12(4):e0175048.
   PubMed Web of Science ®Google Scholar
• Xu T, Wang Z, Dong M, et al. Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer. Aging. 2020;12(17):17305–17327.
   PubMedGoogle Scholar
• Tomioka N, Azuma M, Ikarashi M, et al. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer. 2018;25(1):34–42.
   PubMed Web of Science ®Google Scholar
• Park IH, Kong SY, Ro JY, et al. Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer. Clin Breast Cancer. 2016;16(1):51–58.
   PubMed Web of Science ®Google Scholar
• Lasoudris F, Cousin C, Prevost-Blondel A, et al. IL4I1: an inhibitor of the CD8+ antitumor T-cell response in vivo. Eur J Immunol. 2011;41(6):1629–1638.
   PubMed Web of Science ®Google Scholar
• Bod L, Lengagne R, Wrobel L, et al. IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma. Oncoimmunology. 2017;6(3):e1278331.
   PubMed Web of Science ®Google Scholar
• Yue Y, Huang W, Liang J, et al. IL4I1 is a novel regulator of M2 macrophage polarization that Can inhibit T cell activation via L-tryptophan and arginine depletion and IL-10 production. PLoS One. 2015;10(11):e0142979.
   PubMed Web of Science ®Google Scholar
• Molinier-Frenkel V, Prévost-Blondel A, Castellano F. The IL4I1 enzyme: a new player in the immunosuppressive tumor microenvironment. Cells. 2019;8(7):757.
   PubMed Web of Science ®Google Scholar
• Mezrich JD, Fechner JH, Zhang X, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198.
   PubMed Web of Science ®Google Scholar
• Sadik A, Somarribas Patterson LF, Ozturk S, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020;182(5):1252–1270.e34.
   PubMed Web of Science ®Google Scholar
• Chai Z, Yang Y, Gu Z, et al. Recombinant viral capsid protein L2 (rVL2) of HPV 16 suppresses cell proliferation and glucose metabolism via ITGB7/C/EBPbeta signaling pathway in cervical cancer cell lines. Onco Targets Ther. 2019;12:10415–10425.
   PubMed Web of Science ®Google Scholar
• Gan L, Meng J, Xu M, et al. Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin beta4/FAK/SOX2/HIF-1alpha signaling pathway in gastric cancer. Oncogene. 2018;37(6):744–755.
   PubMed Web of Science ®Google Scholar
• Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang Y, Liu Y, et al. FUT7 antisense sequence inhibits the expression of FUT7/sLeX and adhesion between embryonic and uterine cells. IUBMB Life. 2008;60(7):461–466.
   PubMed Web of Science ®Google Scholar
• Liang JX, Gao W, Cai L. Fucosyltransferase VII promotes proliferation via the EGFR/AKT/mTOR pathway in A549 cells. Onco Targets Ther. 2017;10:3971–3978.
   PubMed Web of Science ®Google Scholar
• Babiuch K, Dag A, Zhao J, et al. Carbohydrate-specific uptake of fucosylated polymeric micelles by different cancer cell lines. Biomacromolecules. 2015;16(7):1948–1957.
   PubMed Web of Science ®Google Scholar
• Molinier-Frenkel V, Mestivier D, Castellano F. Alterations of the immunosuppressive IL4I1 enzyme activity induced by naturally occurring SNP/mutations. Genes Immun. 2016;17(2):148–152.
   PubMed Web of Science ®Google Scholar
• Pink M, Ratsch BA, Mardahl M, et al. Imprinting of skin/inflammation homing in CD4+ T cells is controlled by DNA methylation within the fucosyltransferase 7 gene. J Immunol. 2016;197(8):3406–3414.
   PubMed Web of Science ®Google Scholar
• Wang J, Xiang H, Lu Y, et al. Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review). Int J Mol Med. 2021;47(4):4888.
   Web of Science ®Google Scholar
• Lim SP, Leung E, Krissansen GW. The beta7 integrin gene (Itgb-7) promoter is responsive to TGF-beta1: defining control regions. Immunogenetics. 1998;48(3):184–195.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–371.
   PubMed Web of Science ®Google Scholar